Market opportunity with the TrovaGene, Inc. (TROV)

May 8, 2012 - PRLog -- TrovaGene, Inc. (TROV) is available at a fraction of its true value. But not for long. Here's why:

TrovaGene is developing a patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine. To simplify: TROV is targeting a $40B+ market in oncology alone. (http://www.trovagene.com/Media/120117_Introduction_to_TrovaGene_Presentation_PPTX.pdf )

Everything we see points to TROV being a candidate for a broader market exchange (i.e. a national exchange) listing. This will allow for investors globally to invest in TROV at the same time. Here are the particulars:

- TrovaGene is fully reporting;

- In 2011, TrovaGene reacquired ownership of the worldwide rights and control over its patent estate for transrenal technology, including oncology applications, from Sequenom, Inc. ;

- Executive team (one of the major aspects for the success):

Antonius Schuh, Ph.D. CEO of TrovaGene
Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (SRNE.PK) that merged in 2009 with a public company supported by Phillip Frost and the Frost Group. Dr. Schuh also served as the founding CEO of AviaraDx, Inc. that was sold to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Dr. Schuh served as CEO of Arcturus Bioscience, Inc., that was sold to Molecular Devices, Inc.

Gabriele M. Cerrone, Director of TrovaGene (http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=83...)
Founder and Chairman of FermaVir Pharmaceuticals that was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company. Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

- From the TrovaGene's announcement of the Trans-Renal K-RAS program:
(http://finance.yahoo.com/news/trovagene-announces-validat...)
"The Company plans to enter into collaborative agreements, providing access to patient samples, with leading endocrine oncology clinical sites in the U.S. by June 2012."

TrovaGene must be on the national exchange to face those challenges. Uplisting is imminent.

Look for TROV to trade at $3+ on a big board exchange - a "buy & hold" opportunity, that's all there's to it.

About TrovaGene, Inc.:
TrovaGene is a molecular diagnostics company with unique intellectual property around the remarkable discovery that DNA & RNA, present in urine could be diagnostic of diseases such as cancer and infection. TrovaGene’s revolutionary molecular diagnostic technology is setting out to change the way medicine is practiced, through simple, non-invasive diagnostic sampling of these nucleic acids leading to earlier detection of serious illness.